Brought to you by 
BrainCells to raise $17.7mm with Series A financing
18 Oct 2005
Executive Summary
BrainCells (therapeutics for CNS disorders) has raised $8mm of the $17.7mm its backers have committed to its Series A round. (It will get the remaining money when it reaches certain milestones.) Technology Partners and seed investors Oxford Bioscience Partners and Bay City Capital co-led the round. AM Pappas, NeuroVentures, and several individuals--CEO Harry Hixson, Matthias Bowman, and scientific founders Fred H. Gage of the Salk Institute for Biological Studies and Eric Kandel of Columbia University--also participated in the financing.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BrainCells to raise $17.7mm with Series A financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice